Trials / No Longer Available
No Longer AvailableNCT04678466
Flotetuzumab Expanded Access Program
An Expanded Access Program Providing Flotetuzumab in the Treatment of Acute Myeloid Leukemia Patients in Single, Individually-approved Patients
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- MacroGenics · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of the Expanded Access program is to provide flotetuzumab to patients with acute myeloid leukemia (AML) for whom potential benefit justifies potential treatment risks.
Detailed description
MacroGenics will consider, on a case-by-case basis, requests by treating physicians to file a single patient investigational new drug application for expanded access to flotetuzumab and for MacroGenics to supply flotetuzumab for single patient use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | flotetuzumab | CD123 x CD3 bispecific DART® antibody |
Timeline
- First posted
- 2020-12-22
- Last updated
- 2022-05-31
Source: ClinicalTrials.gov record NCT04678466. Inclusion in this directory is not an endorsement.